培高利特治疗脑卒中后高级神经活动障碍

Pergolide in treatment of high nervous activity disturbance after stroke

目的:评价应用多巴胺激动剂———培高利特治疗脑卒中后高级神经活动障碍的疗效和安全性。方法:对98例脑卒中病人给予培高利特治疗,96例对照组给予吡拉西坦治疗。应用中国中风神经功能缺损评分(CSS)区分2组病人的病情,应用Barthel指数的改变评价治疗前后日常生活能力(ADL)。结果:治疗14d后,2组病人ADL差值差异无显著意义(P>0.05)。治疗21d和3mo后,治疗组中重度病人的ADL差值差异均有显著意义(P<0.05)。治疗组中非流利性失语语言恢复人数较对照组差异有显著意义(P<0.05),运动不能性缄默症消失人数差异有非常显著意义(P<0.01)。结论:脑卒中引起的高级神经活动障碍,使用培高利特后有一定改善,且安全性较好。

AIM: To evaluate the efficacy and the safety of dopamine agonist—pergolide in treatment of higher nervous activity disturbance after stroke. METHODS: Pergolide was given to 98 patients with stroke and piracetam to 96 patients as control group. CSS was used to score the seriousness of the patients to be studied. The Barthel index was adopted to evaluate the abilities in daily life (ADL) before and after the treatment. RESULTS: After the treatment for 14 d, the ADL showed no significant difference between 2 groups (P>0.05). After 21 d and 3 mo treatment, ADL of 2 groups with most serious nervous activity disturbance showed significance difference ((P<0.05)). The recovery of non-fluent aphasia in the patients of treatment group indicated significant difference comparing with control group (P<0.05). The recovery of the akinetic mutism revealed more significant difference (P<(0.01).) CONCLUSION: Dopamine agonist—pergolide can restore higher nervous activity disturbance after stroke. The results suggest that the more serious of the disease is the more obvious the improvement. The adverse reactions are slight, so adaministration of pergolide is safe.